Expertise in
13
conditions

Wolfgang D. Wick

Heidelberg, BW, DE 
Expertise in
13
conditions
Heidelberg, BW, DE 

Overview

Wolfgang Wick practices practicing medicine in Heidelberg, Germany.

Mr. Wick is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Gliomatosis Cerebri, and Thrombectomy.

He is actively involved in clinical research, co-authoring 632 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Heidelberg, BW, Germany
Other Locations
Mannheim, BW, Germany
Tuebingen, BW, Germany
Salem, BW, Germany
Germany
Munich, BY, Germany
Magdeburg, ST, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery
An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery
Enrollment Status: Unknown
Publish Date: October 20, 2022
Intervention Type: Biological
Study Drugs: VXM01, Avelumab
Study Phase: Phase 1/Phase 2
A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma
A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma
Enrollment Status: Terminated
Publish Date: November 01, 2017
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

632 Total Publications

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.
Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.
Journal: The Journal of clinical investigation
Published: August 25, 2026

Frequently Asked Questions about Wolfgang D. Wick

Is Wolfgang D. Wick a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Wolfgang D. Wick is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Wolfgang D. Wick participate in research or clinical trials?

Yes. Wolfgang D. Wick has published 632 articles and abstracts on conditions like Astrocytoma. You can view a list of Wolfgang D. Wick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wick's expertise for a condition
ConditionClose
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile